Advertisement
UK markets close in 5 hours 58 minutes
  • FTSE 100

    8,050.75
    +26.88 (+0.33%)
     
  • FTSE 250

    19,677.36
    +77.97 (+0.40%)
     
  • AIM

    751.73
    +2.55 (+0.34%)
     
  • GBP/EUR

    1.1588
    -0.0001 (-0.01%)
     
  • GBP/USD

    1.2359
    +0.0008 (+0.07%)
     
  • Bitcoin GBP

    53,599.75
    +203.23 (+0.38%)
     
  • CMC Crypto 200

    1,423.60
    +8.84 (+0.63%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    82.17
    +0.27 (+0.33%)
     
  • GOLD FUTURES

    2,309.10
    -37.30 (-1.59%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    17,972.54
    +111.74 (+0.63%)
     
  • CAC 40

    8,068.67
    +28.31 (+0.35%)
     

What’s Abbott Laboratories’ Current Valuation?

What’s Abbott Laboratories’ Current Valuation?

As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x. The forward estimate is lower than the current PE ratio, which reflects the analysts’ expectations for higher company earnings over the next 12 months. To calculate the forward PE for a company, the current stock price of the company is divided by its earnings estimates for the next 12 months.